ArticleCancer cytopathology2026
Prediction of lymphocyte-predominant breast cancer using microRNA expression in cytology specimens.
Article in Cancer cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor-infiltrating lymphocytes are prognostic and predictive biomarkers of breast cancer; however, conventional assessment is hindered by invasiveness and subjective evaluation, limiting clinical reproducibility. This study investigated the utility of microRNA (miRNA) profiles in predicting lymphocyte-predominant breast cancer (LPBC).
methodsThis study included 56 patients with breast cancer who underwent fine-needle aspiration cytology at the time of diagnosis (28 LPBC and 28 non-LPBC cases). Total RNA was extracted from cytology smear specimens, and the expression levels of six candidate miRNAs (miR-30a-3p, miR-187, miR-196b, miR-1247, miR-4485, and miR-6510) were quantified using reverse-transcriptase polymerase chain reaction. The performance in identifying LPBC was evaluated using receiver operating characteristic curve analysis and logistic regression models.
resultsAll six miRNAs showed significantly lower expression levels in the LPBC group than in the non-LPBC group (all p < .05). Receiver operating characteristic curve analysis demonstrated moderate to high diagnostic accuracy, with an area under the curve of 0.708 for miR-30a-3p, 0.739 for miR-187, 0.783 for miR-196b, 0.777 for miR-1247, 0.790 for miR-4485, and 0.673 for miR-6510. Multivariate analysis further identified each miRNA as an independent diagnostic predictor for LPBC.
conclusionsmiRNA profiling of cytologic samples enabled the objective identification of LPBC. These findings suggest that specific miRNA expression patterns reflect the tumor immune microenvironment and can be used to evaluate the status of tumor-infiltrating lymphocytes in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.